Renal Anemia - Pipeline Review, H1 2015
Summary
Global Markets Directs, Renal Anemia - Pipeline Review, H1 2015, provides an overview of the Renal Anemias therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Renal Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective RandD development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Renal Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Renal Anemia Overview 9
Therapeutics Development 10
Pipeline Products for Renal Anemia - Overview 10
Pipeline Products for Renal Anemia - Comparative Analysis 11
Renal Anemia - Therapeutics under Development by Companies 12
Renal Anemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Renal Anemia - Products under Development by Companies 18
Renal Anemia - Companies Involved in Therapeutics Development 21
3SBio Inc. 21
Acceleron Pharma, Inc. 22
Akebia Therapeutics, Inc. 23
Amgen Inc. 24
Aprogen, Inc. 25
Bayer AG 26
BIOCAD 27
CCM Duopharma Biotech Bhd. 28
Daiichi Sankyo Company, Limited 29
Dong-A Socio Group 30
FibroGen, Inc. 31
GlaxoSmithKline plc 32
Hospira, Inc. 33
Intas Pharmaceuticals Ltd. 34
Japan Tobacco Inc. 35
JCR Pharmaceuticals Co., Ltd. 36
Jiangsu Hansoh Pharmaceutical Co., Ltd. 37
Medgenics Inc. 38
Myungmoon pharmaceutical Co.,Ltd. 39
Panacea Biotec Limited 40
Pieris AG 41
ProMetic Life Sciences Inc. 42
Sandoz International GmbH 43
Zydus Cadila Healthcare Limited 44
Renal Anemia - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
AKB-6548 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RD Progress 54
daprodustat - Drug Profile 55
Product Description 55
Mechanism of Action 55
RD Progress 55
darbepoetin alfa - Drug Profile 57
Product Description 57
Mechanism of Action 57
RD Progress 57
darbepoetin alfa - Drug Profile 58
Product Description 58
Mechanism of Action 58
RD Progress 58
darbepoetin alfa - Drug Profile 59
Product Description 59
Mechanism of Action 59
RD Progress 59
darbepoetin alfa - Drug Profile 60
Product Description 60
Mechanism of Action 60
RD Progress 60
darbepoetin alfa - Drug Profile 61
Product Description 61
Mechanism of Action 61
RD Progress 61
darbepoetin alfa (recombinant) - Drug Profile 62
Product Description 62
Mechanism of Action 62
RD Progress 62
DS-1093 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RD Progress 64
EPO-018B - Drug Profile 65
Product Description 65
Mechanism of Action 65
RD Progress 65
epoetin alfa - Drug Profile 66
Product Description 66
Mechanism of Action 66
RD Progress 66
epoetin alfa (recombinant) - Drug Profile 67
Product Description 67
Mechanism of Action 67
RD Progress 67
epoetin zeta - Drug Profile 69
Product Description 69
Mechanism of Action 69
RD Progress 69
FG-2216 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RD Progress 71
FMX-8 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RD Progress 73
JTZ-951 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RD Progress 74
MDGN-201 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RD Progress 75
MM-P01-01 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RD Progress 76
molidustat - Drug Profile 77
Product Description 77
Mechanism of Action 77
RD Progress 77
NuPIAO - Drug Profile 79
Product Description 79
Mechanism of Action 79
RD Progress 79
PBI-1402 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RD Progress 80
PBI-4050 - Drug Profile 82
Product Description 82
Mechanism of Action 82
RD Progress 82
PEG-EPO - Drug Profile 83
Product Description 83
Mechanism of Action 83
RD Progress 83
Peg-EPO - Drug Profile 84
Product Description 84
Mechanism of Action 84
RD Progress 84
PRS-080 - Drug Profile 85
Product Description 85
Mechanism of Action 85
RD Progress 85
Recombinant Protein for Renal Anemia - Drug Profile 86
Product Description 86
Mechanism of Action 86
RD Progress 86
roxadustat - Drug Profile 87
Product Description 87
Mechanism of Action 87
RD Progress 87
sotatercept - Drug Profile 90
Product Description 90
Mechanism of Action 90
RD Progress 90
Renal Anemia - Recent Pipeline Updates 93
Renal Anemia - Dormant Projects 110
Renal Anemia - Discontinued Products 111
Renal Anemia - Product Development Milestones 112
Featured News Press Releases 112
Mar 27, 2015: Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgens Epogen 112
Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN 112
Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat 114
Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease 114
Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201 115
Sep 26, 2013: ProMetics Lead Drug Candidate, PBI-4050, Enters Clinical Program 116
Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan 116
Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease 117
Apr 16, 2013: Amgen To Pay US $24.9m To Resolve False Claims Act Allegations 117
Jan 16, 2013: Amgen Announces Top-Line Results Of Phase III Aranesp RED-HF Trial 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121
List Of Tables
Number of Products under Development for Renal Anemia, H1 2015 10
Number of Products under Development for Renal Anemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Development by Companies, H1 2015 (Contd..2) 20
Renal Anemia - Pipeline by 3SBio Inc., H1 2015 21
Renal Anemia - Pipeline by Acceleron Pharma, Inc., H1 2015 22
Renal Anemia - Pipeline by Akebia Therapeutics, Inc., H1 2015 23
Renal Anemia - Pipeline by Amgen Inc., H1 2015 24
Renal Anemia - Pipeline by Aprogen, Inc., H1 2015 25
Renal Anemia - Pipeline by Bayer AG, H1 2015 26
Renal Anemia - Pipeline by BIOCAD, H1 2015 27
Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H1 2015 28
Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29
Renal Anemia - Pipeline by Dong-A Socio Group, H1 2015 30
Renal Anemia - Pipeline by FibroGen, Inc., H1 2015 31
Renal Anemia - Pipeline by GlaxoSmithKline plc, H1 2015 32
Renal Anemia - Pipeline by Hospira, Inc., H1 2015 33
Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 34
Renal Anemia - Pipeline by Japan Tobacco Inc., H1 2015 35
Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2015 36
Renal Anemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 37
Renal Anemia - Pipeline by Medgenics Inc., H1 2015 38
Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2015 39
Renal Anemia - Pipeline by Panacea Biotec Limited, H1 2015 40
Renal Anemia - Pipeline by Pieris AG, H1 2015 41
Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H1 2015 42
Renal Anemia - Pipeline by Sandoz International GmbH, H1 2015 43
Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 44
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Stage and Target, H1 2015 47
Number of Products by Stage and Mechanism of Action, H1 2015 49
Number of Products by Stage and Route of Administration, H1 2015 51
Number of Products by Stage and Molecule Type, H1 2015 53
Renal Anemia Therapeutics - Recent Pipeline Updates, H1 2015 93
Renal Anemia - Dormant Projects, H1 2015 110
Renal Anemia - Discontinued Products, H1 2015 111
List Of Figures
Number of Products under Development for Renal Anemia, H1 2015 10
Number of Products under Development for Renal Anemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Top 10 Targets, H1 2015 46
Number of Products by Stage and Top 10 Targets, H1 2015 47
Number of Products by Top 10 Mechanism of Actions, H1 2015 48
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 49
Number of Products by Top 10 Routes of Administration, H1 2015 50
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 51
Number of Products by Top 10 Molecule Types, H1 2015 52
Number of Products by Stage and Top 10 Molecule Types, H1 2015 53
